DOCSLIB.ORG

X‐Ray Crystallography, Magnetometry, High‐Frequency

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
X‐Ray Crystallography, Magnetometry, High‐Frequency Erschienen in: European Journal of Inorganic Chemistry ; 2018 (2018), 6. - S. 713-721 https://dx.doi.org/10.1002/ejic.201701459 The [Fe{(SePPh2)2N}2] Complex Revisited: X-ray Crystallography, Magnetometry, High-Frequency EPR, and Mössbauer Studies II Reveal Its Tetrahedral Fe Se4 Coordination Sphere Eleftherios Ferentinos,[a] Spyros Chatziefthimiou,[b][‡] Athanassios K. Boudalis,[b][‡‡] Michael Pissas,[b] Guinevere Mathies,[c][‡‡‡] Peter Gast,[c] Edgar J. J. Groenen,*[c] Yiannis Sanakis,*[b] and Panayotis Kyritsis*[a] Abstract: The synthesis and characterization of complex electronic structure of 1 was elucidated by magnetometry, [Fe{(SePPh2)2N}2](1) is described. X-ray crystallography shows high-frequency EPR, and Mössbauer spectroscopic studies, that this system contains a tetrahedral FeSe4 coordination which reveal zero-field splitting (ZFS) parameters typical of high sphere. The structural features of 1 are compared with those of spin S = 2 tetrahedral FeII sites. Accurate ZFS parameters (D = similar first row transition element complexes, including a re- +8.22 cm–1, E/D = 0.104) were obtained by analysis of the EPR cently reported preparation of [Fe{(SePPh2)2N}2](1SP) exhibiting spectra and compared with those of the analogous a highly unusual square planar FeSe4 coordination sphere. The [Fe{(SPPh2)2N}2] complex. Introduction its active site have been investigated.[6] The effects of replacing Cys by Se-Cys have been investigated in various metallo- Selenium exhibits a rich and intensively investigated biological proteins, such as metallothionein,[7] Cyt P ,[8] azurin,[9] and chemistry.[1] In that respect, the bioinorganic chemistry of sel- 450 sulfite oxidase.[10] Moreover, sulfide S2– has been replaced by enium, mainly expressed via coordination of either seleno- selenide Se2– in the iron-sulfur active site of numerous cystein (Se-Cys) or selenide (Se2–) to transition metals in metal- proteins,[11] like the [4Fe-4S] cluster of [FeFe]-hydrogenase[12a] loproteins or synthetic analogues, has been extensively ex- (Se/S substitution has also been carried out in the [2Fe] cluster plored. More specifically, X-ray crystallography has revealed the of the latter[12b]), the iron protein of nitrogenase,[13] the photo- coordination of Se-Cys to nickel in the Ni-Fe-Se hydrogenase,[2] system I polypeptide PsaC,[14] aconitase,[15] high potential iron- as well as to molybdenum in the active site of formate dehydro- sulfur protein,[16] as well as [2Fe-2S][17] and 2[4Fe-4S] ferredox- genase[3] and nicotinate dehydrogenase.[4] The Ni-Fe-Se hydro- ins.[18] genase has been employed for the photocatalytic production [5] As far as the synthetic bioinorganic chemistry of selenium of H2 under increased O2 levels, while chemical analogues of is concerned, a range of multinuclear clusters containing iron 2– [19] [a] Inorganic Chemistry Laboratory, Department of Chemistry, coordinated to Se and various thiols, as well as tungsten- National and Kapodistrian University of Athens, iron-sulfur/selenium clusters,[20] have been investigated by Panepistimiopolis 15771, Athens, Greece Holm and co-workers. The coordination of selenium to transi- E-mail: [email protected] tion metals has also been explored by employing the so called http://users.uoa.gr/~kyritsis/home.html ′ ′ [b] Institute of Nanoscience and Nanotechnology, N.C.S.R. “Demokritos”, dichalcogenidoimidodiphosphinato ligands, R2P(E)NHP(E )R 2 ′ [21] Aghia Paraskevi 15310, Attiki, Greece (E, E′ =O,S,Se,Te;R,R = alkyl or aryl groups). Among this – [22] E-mail: [email protected] family of chelating ligands, L = [Ph2P(Se)NP(Se)Ph2] , contain- https://inn.demokritos.gr/en/prosopiko/i.sanakis ing E = E′ = Se as donor atoms, and R = R′ = Ph as peripheral [c] Huygens-Kamerlingh Onnes Laboratory, Department of Physics, groups bonded to the P atoms of the P–N–P backbone, has Leiden University, Niels Bohrweg 2, 2333 CA Leiden, The Netherlands afforded the following structurally characterized homoleptic E-mail: [email protected] complexes with first series transition metal ions (structures de- https://www.universiteitleiden.nl/en/staffmembers/edgar-groenen#tab-1 posited in the Cambridge Structural Database, CSD[23]): octahe- [‡] Present address: EMBL-Hamburg c/o Deutsches Elektronen-Synchrotron, III [24] [24] II [25] [26] dral M L3,M=V, Cr, tetrahedral M L2,M=Mn, Co, Hamburg, Germany [27] II [28] I [29] [‡‡] Present address: Institut de Chimie de Strasbourg Zn, square planar Ni L2 and tetranuclear [Cu 4L3]BF4. – (UMR 7177, CNRS-Unistra), Université de Strasbourg, With respect to the coordination of [Ph2P(Se)NP(Se)Ph2] to 4 rue Blaise Pascal, CS 90032, 67081 Strasbourg, France FeII, it should first be noted that the following literature com- [‡‡‡] Present address: Department of Chemistry, University of Konstanz, plexes have been shown, by X-ray crystallography, to unequivo- Universitätsstraße 10, 78464 Konstanz, Germany Supporting information and ORCID(s) from the author(s) for this article are cally contain a tetrahedral FeSe4 coordination sphere: [30] [31] available on the WWW under https://doi.org/10.1002/ejic.201701459. [N(CH3CH2)4]2[Fe(SePh)4], [Fe(1,10-phen)3][Fe(SePh)4], 713 Konstanzer Online-Publikations-System (KOPS) URL: http://nbn-resolving.de/urn:nbn:de:bsz:352-2-e7hbu1honj565 [32] [33] [PPh4]2[Fe(Se4)2], [N(CH3)4]2[Fe{SeC(CH3)3}4], [bis(1,3-di- X-ray Crystallography and IR Spectroscopy tert-butyl-1H-imidazol-3-ium)] [Fe(SePh) ],[34] [Fe{(SePiPr ) - 2 4 2 2 The molecular structure of 1 is shown in Figure 1. The crystal N} ][35] and [Fe(dmise) ][BF ] , dmise = N,N′-dimethylimidazole- 2 4 4 2 data, as well as the refinement statistics, of the structure of 1 selone.[36] In addition, on the basis of spectroscopic and room are listed in Table S1 (Supporting Information). Selected bond temperature magnetometry studies, the [Fe{(SePPh ) CH} ] 2 2 2 lengths and angles of 1, are listed in Tables S2 and S3, respec- complex, bearing a ligand which is similar to L, has been pro- [37] tively. posed to also contain a tetrahedral FeSe4 core. Based on the above, the recently reported crystal structure of a preparation of FeL2 containing a square planar FeSe4 coordination sphere [38] (1SP, CSD code FOMWIP) was rather unexpected and prompted us to revisit the FeL2 system. X-ray crystallography revealed that our preparation of FeL2 (1), presented herein, exhibits clearly a tetrahedral FeSe4 coordi- nation sphere. The magnetic and spectroscopic properties of 1 were investigated by magnetometry, as well as by IR, high- frequency EPR and Mössbauer spectroscopy. Comparisons are [38] [35] being made with the properties of 1SP, [Fe{(SePiPr2)2N}2] [39] and [Fe{(SPPh2)2N}2] complexes. Recent high-frequency EPR II studies of the latter have revealed distinct S =2Fe sites, the Figure 1. Molecular structure of complex 1. The H atoms are omitted for spin-Hamiltonian parameters of which have been accurately de- clarity. Color coding: Iron (brown), selenium (magenta), phosphorus (light termined.[39b] This complex is a synthetic analogue of the re- brown), nitrogen (blue), carbon (gray). duced form of the iron-sulfur protein rubredoxin, which con- The FeSe core of complex 1 exhibits a distorted tetrahedral tains a [Fe(S-Cys) ] active site.[40] To our best knowledge, re- 4 4 geometry, as reflected by the magnitude of the Se–Fe–Se placement of the iron-coordinating Cys residues of rubredoxin angles which lie between 101.7(1)° and 115.7(1)° (Table S2). The by Se-Cys has not yet been reported. two endocyclic Se–Fe–Se bite angles amount to 115.7(1)° and In the following, the interplay between literature tetrahedral are similar to those of the [Fe{(SePiPr ) N} ][35] and and square planar FeII complexes, including their spin states 2 2 2 [M{(SePPh ) N} ],M=Mn,[25] Co,[26] Zn,[27] complexes listed in and Mössbauer spectroscopic signatures, is analyzed. Moreover, 2 2 2 Table 1. The dihedral angle between the planes defined by the the effects on the D (axial) and E (rhombic) zero-field splitting endocyclic Se–Fe–Se angles of complex 1 is 86.8°, comparable (ZFS) components of FeII coordination to [Ph P(Se)NP(Se)Ph ]–, 2 2 to those of the [M{(SePPh ) N} ], M = Mn, Co, Zn, complexes as opposed to [Ph P(S)NP(S)Ph ]–,[39b] in a similar tetrahedral 2 2 2 2 2 (Table 1). The significantly smaller values, 81.3° and 82.4°, re- S =2FeE site,E=S,Se,arealso discussed. 4 spectively, for the sites 1 and 2 of the recently reported [Fe{(SePiPr2)2N}2] complex reveal a more profound deviation from the value (90.0°) of the ideal tetrahedral structure, appar- Results and Discussion ently imposed by the iPr peripheral groups of the ligand. In addition, the latter structure exhibits a different space group Chemical Synthesis compared with the rest of those listed in Table 1. The FeSePNPSe rings in the structure of 1 adopt a pseudo-boat con- Complex 1 was synthesized by mixing FeCl2 and the formation, with the P and Se atoms at the apices, in agreement – [Ph2P(Se)NP(Se)Ph2] ligand, under anaerobic conditions, in or- with the structure of the analogous Mn, Co, Zn complexes der to minimize the formation of byproduct FeIII species. A dif- (Table 1). ferent preparation of the same complex (1SP) has been recently The averaged P–Se and P–N bond lengths of [38] reported. The proposed crystal structure of 1SP, containing a Ph2P(Se)NHP(Se)Ph2 and 1 are listed in Table 2. Close inspection square planar FeSe4 coordination sphere, will be compared, in reveals that the average P–Se bond length of 1 is increased the following, with that of the present complex 1.
Load more

Recommended publications
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Genomic Evidence of Reactive Oxygen Species Elevation in Papillary Thyroid Carcinoma with Hashimoto Thyroiditis
    Endocrine Journal 2015, 62 (10), 857-877 Original Genomic evidence of reactive oxygen species elevation in papillary thyroid carcinoma with Hashimoto thyroiditis Jin Wook Yi1), 2), Ji Yeon Park1), Ji-Youn Sung1), 3), Sang Hyuk Kwak1), 4), Jihan Yu1), 5), Ji Hyun Chang1), 6), Jo-Heon Kim1), 7), Sang Yun Ha1), 8), Eun Kyung Paik1), 9), Woo Seung Lee1), Su-Jin Kim2), Kyu Eun Lee2)* and Ju Han Kim1)* 1) Division of Biomedical Informatics, Seoul National University College of Medicine, Seoul, Korea 2) Department of Surgery, Seoul National University Hospital and College of Medicine, Seoul, Korea 3) Department of Pathology, Kyung Hee University Hospital, Kyung Hee University School of Medicine, Seoul, Korea 4) Kwak Clinic, Okcheon-gun, Chungbuk, Korea 5) Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, Uijeongbu, Korea 6) Department of Radiation Oncology, Seoul St. Mary’s Hospital, Seoul, Korea 7) Department of Pathology, Chonnam National University Hospital, Kwang-Ju, Korea 8) Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 9) Department of Radiation Oncology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea Abstract. Elevated levels of reactive oxygen species (ROS) have been proposed as a risk factor for the development of papillary thyroid carcinoma (PTC) in patients with Hashimoto thyroiditis (HT). However, it has yet to be proven that the total levels of ROS are sufficiently increased to contribute to carcinogenesis. We hypothesized that if the ROS levels were increased in HT, ROS-related genes would also be differently expressed in PTC with HT. To find differentially expressed genes (DEGs) we analyzed data from the Cancer Genomic Atlas, gene expression data from RNA sequencing: 33 from normal thyroid tissue, 232 from PTC without HT, and 60 from PTC with HT.
    [Show full text]
  • European Patent Office U.S. Patent and Trademark Office
    EUROPEAN PATENT OFFICE U.S. PATENT AND TRADEMARK OFFICE CPC NOTICE OF CHANGES 89 DATE: JULY 1, 2015 PROJECT RP0098 The following classification changes will be effected by this Notice of Changes: Action Subclass Group(s) Symbols deleted: C12Y 101/01063 C12Y 101/01128 C12Y 101/01161 C12Y 102/0104 C12Y 102/03011 C12Y 103/01004 C12Y 103/0103 C12Y 103/01052 C12Y 103/99007 C12Y 103/9901 C12Y 103/99013 C12Y 103/99021 C12Y 105/99001 C12Y 105/99002 C12Y 113/11013 C12Y 113/12012 C12Y 114/15002 C12Y 114/99028 C12Y 204/01119 C12Y 402/01052 C12Y 402/01058 C12Y 402/0106 C12Y 402/01061 C12Y 601/01025 C12Y 603/02027 Symbols newly created: C12Y 101/01318 C12Y 101/01319 C12Y 101/0132 C12Y 101/01321 C12Y 101/01322 C12Y 101/01323 C12Y 101/01324 C12Y 101/01325 C12Y 101/01326 C12Y 101/01327 C12Y 101/01328 C12Y 101/01329 C12Y 101/0133 C12Y 101/01331 C12Y 101/01332 C12Y 101/01333 CPC Form – v.4 CPC NOTICE OF CHANGES 89 DATE: JULY 1, 2015 PROJECT RP0098 Action Subclass Group(s) C12Y 101/01334 C12Y 101/01335 C12Y 101/01336 C12Y 101/01337 C12Y 101/01338 C12Y 101/01339 C12Y 101/0134 C12Y 101/01341 C12Y 101/01342 C12Y 101/03043 C12Y 101/03044 C12Y 101/98003 C12Y 101/99038 C12Y 102/01083 C12Y 102/01084 C12Y 102/01085 C12Y 102/01086 C12Y 103/01092 C12Y 103/01093 C12Y 103/01094 C12Y 103/01095 C12Y 103/01096 C12Y 103/01097 C12Y 103/0701 C12Y 103/08003 C12Y 103/08004 C12Y 103/08005 C12Y 103/08006 C12Y 103/08007 C12Y 103/08008 C12Y 103/08009 C12Y 103/99032 C12Y 104/01023 C12Y 104/01024 C12Y 104/03024 C12Y 105/01043 C12Y 105/01044 C12Y 105/01045 C12Y 105/03019 C12Y 105/0302
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]
  • Electronic Supplementary Information
    Electronic Supplementary Material (ESI) for Energy & Environmental Science. This journal is © The Royal Society of Chemistry 2018 Electronic Supplementary Information Thermochemical wastewater valorization via enhanced microbial toxicity tolerance Lahiru N. Jayakody1, Christopher W. Johnson1, Jason M. Whitham2, Richard J. Giannone2, Brenna A. Black1, Nicholas S. Cleveland1, William E. Michener1, Jessica L. Olstad1, Derek R. Vardon1, Robert C. Brown3, Dawn M. Klingeman2, Steven D. Brown2, 4, Robert L. Hettich2, Adam M. Guss2, Gregg T. Beckham1, * 1National Bioenergy Center, National Renewable Energy Laboratory, Golden CO 80401 2Oak Ridge National Laboratory, 1 Bethel Valley Rd, Oak Ridge, TN 37830 3Bioeconomy Institute and Department of Mechanical Engineering, Iowa State University, Ames, IA 50011, USA 4LanzaTech, Inc., Skokie, IL 60077, USA *Email: [email protected] Supplemental Materials and Methods Determination of the combinational inhibitory effect of FPF chemical functional groups A three-level partial factorial growth experiment was performed using synthetic medium containing combinations of the most abundant compounds present in FPF based on their functional groups, including FPF-aldehyde, FPF-ketone, FPF-acids, and FPF-phenolics. Level 1 contained 0 % (v/v), level 2 contained 0.02 % (v/v), and level 3 contained 0.03 % (v/v); 9-ineractions were tested according to Taguchi Orthogonal "L" Array design metrics (ESI Fig. S2). 200 µL of M9 medium-containing 20 mM glucose supplemented with various concentrations of FPF components was added to the wells of a Bioscreen C microplate, P. putida KT2440 cells were added to reach an initial cell density of OD600=0.1, and the plate was incubated at 30°C with medium shaking.
    [Show full text]
  • Supplemental Figures 04 12 2017
    Jung et al. 1 SUPPLEMENTAL FIGURES 2 3 Supplemental Figure 1. Clinical relevance of natural product methyltransferases (NPMTs) in brain disorders. (A) 4 Table summarizing characteristics of 11 NPMTs using data derived from the TCGA GBM and Rembrandt datasets for 5 relative expression levels and survival. In addition, published studies of the 11 NPMTs are summarized. (B) The 1 Jung et al. 6 expression levels of 10 NPMTs in glioblastoma versus non‐tumor brain are displayed in a heatmap, ranked by 7 significance and expression levels. *, p<0.05; **, p<0.01; ***, p<0.001. 8 2 Jung et al. 9 10 Supplemental Figure 2. Anatomical distribution of methyltransferase and metabolic signatures within 11 glioblastomas. The Ivy GAP dataset was downloaded and interrogated by histological structure for NNMT, NAMPT, 12 DNMT mRNA expression and selected gene expression signatures. The results are displayed on a heatmap. The 13 sample size of each histological region as indicated on the figure. 14 3 Jung et al. 15 16 Supplemental Figure 3. Altered expression of nicotinamide and nicotinate metabolism‐related enzymes in 17 glioblastoma. (A) Heatmap (fold change of expression) of whole 25 enzymes in the KEGG nicotinate and 18 nicotinamide metabolism gene set were analyzed in indicated glioblastoma expression datasets with Oncomine. 4 Jung et al. 19 Color bar intensity indicates percentile of fold change in glioblastoma relative to normal brain. (B) Nicotinamide and 20 nicotinate and methionine salvage pathways are displayed with the relative expression levels in glioblastoma 21 specimens in the TCGA GBM dataset indicated. 22 5 Jung et al. 23 24 Supplementary Figure 4.
    [Show full text]
  • Supplementary Table S1. Relative Change in Proteins Associated with Heme Biosynthesis and Degradation
    Supplementary Table S1. Relative change in proteins associated with heme biosynthesis and degradation. hPXR mPxr–/– Protein Gene RIF/INH INH RIF RIF/INH p Value 5-aminolevulinate synthase Alas1 1.90 2.61 1.05 1.41 0.28 5-aminolevulinate synthase Alas2 0.86 1.38 0.73 1.18 0.018 Delta-aminolevulinic acid Alad 0.96 1.00 1.02 0.95 0.75 dehydratase Porphobilinogen deaminase Hmbs 1.04 0.99 1.10 1.05 0.67 Uroporphyrinogen-III synthase Uros 1.19 1.09 1.31 1.38 0.012 Uroporphyrinogen decarboxylase Urod 0.92 1.03 0.94 0.92 0.33 Oxygen-dependent Cpox 1.13 1.04 1.18 1.15 0.20 coproporphyrinogen-III oxidase, Protoporphyrinogen oxidase Ppox 0.69 0.81 0.85 0.83 0.013 Ferrochelatase, Fech 0.39 0.50 0.88 0.43 0.000002 Heme oxygenase 1 Hmox1 1.15 0.86 0.91 1.11 0.34 Heme oxygenase 2 Hmox2 0.96 0.98 0.89 0.88 0.22 Biliverdin reductase A Blvra 0.84 0.92 0.82 0.92 0.032 UDP-glucuronosyltransferase 1-6 Ugt1a6 1.22 0.96 1.10 1.13 0.30 NADPH--cytochrome P450 Por 1.28 0.92 1.18 1.12 0.019 reductase INH, isoniazid; RIF, rifampicin; RIF/INH, rifampicin and isoniazid. Supplementary Table S2. Relative change in protein nuclear receptors. hPXR mPxr–/– Protein Gene RIF/INH INH RIF RIF/INH p Value Aryl hydrocarbon receptor Ahr 1.09 0.91 1.00 1.26 0.092 Hepatocyte nuclear factor Hnf1a 0.87 0.97 0.82 0.79 0.027 1-alpha Hepatocyte nuclear factor Hnf4a 0.95 1.05 0.97 1.08 0.20 4-alpha Oxysterols receptor LXR- Nr1h3 0.94 1.16 1.03 1.02 0.42 alpha Bile acid receptor Nr1h4 1.05 1.17 0.98 1.19 0.12 Retinoic acid receptor Rxra 0.88 1.03 0.83 0.95 0.12 RXR-alpha Peroxisome proliferator-
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur Et Al
    US 2012026.6329A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur et al. (43) Pub. Date: Oct. 18, 2012 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/10 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/24 (2006.01) CI2N 9/02 (2006.01) (75) Inventors: Eric J. Mathur, Carlsbad, CA CI2N 9/06 (2006.01) (US); Cathy Chang, San Marcos, CI2P 2L/02 (2006.01) CA (US) CI2O I/04 (2006.01) CI2N 9/96 (2006.01) (73) Assignee: BP Corporation North America CI2N 5/82 (2006.01) Inc., Houston, TX (US) CI2N 15/53 (2006.01) CI2N IS/54 (2006.01) CI2N 15/57 2006.O1 (22) Filed: Feb. 20, 2012 CI2N IS/60 308: Related U.S. Application Data EN f :08: (62) Division of application No. 1 1/817,403, filed on May AOIH 5/00 (2006.01) 7, 2008, now Pat. No. 8,119,385, filed as application AOIH 5/10 (2006.01) No. PCT/US2006/007642 on Mar. 3, 2006. C07K I4/00 (2006.01) CI2N IS/II (2006.01) (60) Provisional application No. 60/658,984, filed on Mar. AOIH I/06 (2006.01) 4, 2005. CI2N 15/63 (2006.01) Publication Classification (52) U.S. Cl. ................... 800/293; 435/320.1; 435/252.3: 435/325; 435/254.11: 435/254.2:435/348; (51) Int. Cl. 435/419; 435/195; 435/196; 435/198: 435/233; CI2N 15/52 (2006.01) 435/201:435/232; 435/208; 435/227; 435/193; CI2N 15/85 (2006.01) 435/200; 435/189: 435/191: 435/69.1; 435/34; CI2N 5/86 (2006.01) 435/188:536/23.2; 435/468; 800/298; 800/320; CI2N 15/867 (2006.01) 800/317.2: 800/317.4: 800/320.3: 800/306; CI2N 5/864 (2006.01) 800/312 800/320.2: 800/317.3; 800/322; CI2N 5/8 (2006.01) 800/320.1; 530/350, 536/23.1: 800/278; 800/294 CI2N I/2 (2006.01) CI2N 5/10 (2006.01) (57) ABSTRACT CI2N L/15 (2006.01) CI2N I/19 (2006.01) The invention provides polypeptides, including enzymes, CI2N 9/14 (2006.01) structural proteins and binding proteins, polynucleotides CI2N 9/16 (2006.01) encoding these polypeptides, and methods of making and CI2N 9/20 (2006.01) using these polynucleotides and polypeptides.
    [Show full text]
  • All Enzymes in BRENDA™ the Comprehensive Enzyme Information System
    All enzymes in BRENDA™ The Comprehensive Enzyme Information System http://www.brenda-enzymes.org/index.php4?page=information/all_enzymes.php4 1.1.1.1 alcohol dehydrogenase 1.1.1.B1 D-arabitol-phosphate dehydrogenase 1.1.1.2 alcohol dehydrogenase (NADP+) 1.1.1.B3 (S)-specific secondary alcohol dehydrogenase 1.1.1.3 homoserine dehydrogenase 1.1.1.B4 (R)-specific secondary alcohol dehydrogenase 1.1.1.4 (R,R)-butanediol dehydrogenase 1.1.1.5 acetoin dehydrogenase 1.1.1.B5 NADP-retinol dehydrogenase 1.1.1.6 glycerol dehydrogenase 1.1.1.7 propanediol-phosphate dehydrogenase 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) 1.1.1.9 D-xylulose reductase 1.1.1.10 L-xylulose reductase 1.1.1.11 D-arabinitol 4-dehydrogenase 1.1.1.12 L-arabinitol 4-dehydrogenase 1.1.1.13 L-arabinitol 2-dehydrogenase 1.1.1.14 L-iditol 2-dehydrogenase 1.1.1.15 D-iditol 2-dehydrogenase 1.1.1.16 galactitol 2-dehydrogenase 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase 1.1.1.18 inositol 2-dehydrogenase 1.1.1.19 glucuronate reductase 1.1.1.20 glucuronolactone reductase 1.1.1.21 aldehyde reductase 1.1.1.22 UDP-glucose 6-dehydrogenase 1.1.1.23 histidinol dehydrogenase 1.1.1.24 quinate dehydrogenase 1.1.1.25 shikimate dehydrogenase 1.1.1.26 glyoxylate reductase 1.1.1.27 L-lactate dehydrogenase 1.1.1.28 D-lactate dehydrogenase 1.1.1.29 glycerate dehydrogenase 1.1.1.30 3-hydroxybutyrate dehydrogenase 1.1.1.31 3-hydroxyisobutyrate dehydrogenase 1.1.1.32 mevaldate reductase 1.1.1.33 mevaldate reductase (NADPH) 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.35 3-hydroxyacyl-CoA
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0240226A1 Mathur Et Al
    US 20150240226A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0240226A1 Mathur et al. (43) Pub. Date: Aug. 27, 2015 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/16 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/02 (2006.01) CI2N 9/78 (2006.01) (71) Applicant: BP Corporation North America Inc., CI2N 9/12 (2006.01) Naperville, IL (US) CI2N 9/24 (2006.01) CI2O 1/02 (2006.01) (72) Inventors: Eric J. Mathur, San Diego, CA (US); CI2N 9/42 (2006.01) Cathy Chang, San Marcos, CA (US) (52) U.S. Cl. CPC. CI2N 9/88 (2013.01); C12O 1/02 (2013.01); (21) Appl. No.: 14/630,006 CI2O I/04 (2013.01): CI2N 9/80 (2013.01); CI2N 9/241.1 (2013.01); C12N 9/0065 (22) Filed: Feb. 24, 2015 (2013.01); C12N 9/2437 (2013.01); C12N 9/14 Related U.S. Application Data (2013.01); C12N 9/16 (2013.01); C12N 9/0061 (2013.01); C12N 9/78 (2013.01); C12N 9/0071 (62) Division of application No. 13/400,365, filed on Feb. (2013.01); C12N 9/1241 (2013.01): CI2N 20, 2012, now Pat. No. 8,962,800, which is a division 9/2482 (2013.01); C07K 2/00 (2013.01); C12Y of application No. 1 1/817,403, filed on May 7, 2008, 305/01004 (2013.01); C12Y 1 1 1/01016 now Pat. No. 8,119,385, filed as application No. PCT/ (2013.01); C12Y302/01004 (2013.01); C12Y US2006/007642 on Mar. 3, 2006.
    [Show full text]
  • Springer Handbook of Enzymes
    Dietmar Schomburg Ida Schomburg (Eds.) Springer Handbook of Enzymes Alphabetical Name Index 1 23 © Springer-Verlag Berlin Heidelberg New York 2010 This work is subject to copyright. All rights reserved, whether in whole or part of the material con- cerned, specifically the right of translation, printing and reprinting, reproduction and storage in data- bases. The publisher cannot assume any legal responsibility for given data. Commercial distribution is only permitted with the publishers written consent. Springer Handbook of Enzymes, Vols. 1–39 + Supplements 1–7, Name Index 2.4.1.60 abequosyltransferase, Vol. 31, p. 468 2.7.1.157 N-acetylgalactosamine kinase, Vol. S2, p. 268 4.2.3.18 abietadiene synthase, Vol. S7,p.276 3.1.6.12 N-acetylgalactosamine-4-sulfatase, Vol. 11, p. 300 1.14.13.93 (+)-abscisic acid 8’-hydroxylase, Vol. S1, p. 602 3.1.6.4 N-acetylgalactosamine-6-sulfatase, Vol. 11, p. 267 1.2.3.14 abscisic-aldehyde oxidase, Vol. S1, p. 176 3.2.1.49 a-N-acetylgalactosaminidase, Vol. 13,p.10 1.2.1.10 acetaldehyde dehydrogenase (acetylating), Vol. 20, 3.2.1.53 b-N-acetylgalactosaminidase, Vol. 13,p.91 p. 115 2.4.99.3 a-N-acetylgalactosaminide a-2,6-sialyltransferase, 3.5.1.63 4-acetamidobutyrate deacetylase, Vol. 14,p.528 Vol. 33,p.335 3.5.1.51 4-acetamidobutyryl-CoA deacetylase, Vol. 14, 2.4.1.147 acetylgalactosaminyl-O-glycosyl-glycoprotein b- p. 482 1,3-N-acetylglucosaminyltransferase, Vol. 32, 3.5.1.29 2-(acetamidomethylene)succinate hydrolase, p. 287 Vol.
    [Show full text]
  • Nitrite Reduction by Xanthine Oxidase Family Enzymes: a New Class of Nitrite Reductases
    J Biol Inorg Chem (2011) 16:443–460 DOI 10.1007/s00775-010-0741-z ORIGINAL PAPER Nitrite reduction by xanthine oxidase family enzymes: a new class of nitrite reductases Luisa B. Maia • Jose´ J. G. Moura Received: 9 August 2010 / Accepted: 19 November 2010 / Published online: 19 December 2010 Ó SBIC 2010 Abstract Mammalian xanthine oxidase (XO) and Des- Keywords Nitrite reduction Á Nitric oxide formation Á ulfovibrio gigas aldehyde oxidoreductase (AOR) are Molybdenum Á Xanthine oxidase Á Aldehyde members of the XO family of mononuclear molybdoen- oxidoreductase zymes that catalyse the oxidative hydroxylation of a wide range of aldehydes and heterocyclic compounds. Much less Abbreviations known is the XO ability to catalyse the nitrite reduction to AOR Aldehyde oxidoreductase nitric oxide radical (NO). To assess the competence of other DMSOR Dimethylsulfoxide reductase XO family enzymes to catalyse the nitrite reduction and to EPR Electron paramagnetic resonance shed some light onto the molecular mechanism of this Fe/S Iron–sulfur centre reaction, we characterised the anaerobic XO- and AOR- Fe/S–NO Dinitrosyl–iron–sulfur complex catalysed nitrite reduction. The identification of NO as the (MGD) –Fe Ferrous complex of di(N-methyl-D- reaction product was done with a NO-selective electrode 2 glucamine dithiocarbamate) and by electron paramagnetic resonance (EPR) spectros- (MGD) –Fe–NO Mononitrosyl–iron complex copy. The steady-state kinetic characterisation corroborated 2 Mo-enzymes Pterin–molybdenum-containing the XO-catalysed nitrite reduction and demonstrated, for the enzymes first time, that the prokaryotic AOR does catalyse the nitrite NaR Nitrate reductases reduction to NO, in the presence of any electron donor to the NO Nitric oxide radical enzyme, substrate (aldehyde) or not (dithionite).
    [Show full text]